MALCOLM BRENNER to Immunotherapy
This is a "connection" page, showing publications MALCOLM BRENNER has written about Immunotherapy.
Connection Strength
3.394
-
Onward and upward for immuno-oncology. Chin Clin Oncol. 2018 04; 7(2):18.
Score: 0.423
-
Immunotherapy against cancer-related viruses. Cell Res. 2017 Jan; 27(1):59-73.
Score: 0.387
-
Cellular immunotherapy of cancer. Methods Mol Biol. 2010; 651:319-45.
Score: 0.239
-
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther. 2009 Nov; 20(11):1229-39.
Score: 0.236
-
Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009; 15(4):424-9.
Score: 0.223
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.149
-
Emerging Challenges to Cellular Therapy of Cancer. Cancer J. 2023 Jan-Feb 01; 29(1):20-27.
Score: 0.147
-
Cancer vaccines. Hematol Oncol Clin North Am. 2001 Aug; 15(4):741-73.
Score: 0.133
-
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2).
Score: 0.126
-
Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
Score: 0.124
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.086
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.086
-
Immunotherapy of leukemia. Leukemia. 1992; 6 Suppl 1:76-9.
Score: 0.069
-
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther. 2011 Dec; 19(12):2258-68.
Score: 0.067
-
Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60.
Score: 0.067
-
Graft versus leukaemia effects after marrow transplantation in man. Baillieres Clin Haematol. 1991 Jul; 4(3):727-49.
Score: 0.066
-
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther. 2009 Oct; 9(5):396-408.
Score: 0.059
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.058
-
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther. 2009 Sep; 17(9):1616-25.
Score: 0.058
-
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
Score: 0.055
-
Developing T-cell therapies for cancer in an academic setting. Adv Exp Med Biol. 2008; 610:88-99.
Score: 0.052
-
Options for T-cell based therapies. Vox Sang. 2004 Jul; 87 Suppl 2:230-4.
Score: 0.041
-
Cancer vaccines: dream, reality, or nightmare? Clin Exp Med. 2002 Nov; 2(3):109-18.
Score: 0.036
-
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 2002 Jul 01; 100(1):200-7.
Score: 0.035
-
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002 May 01; 99(9):3179-87.
Score: 0.035
-
Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy. 2002; 4(5):433-4.
Score: 0.034
-
Immunotherapy for Hodgkin's disease. Ann Hematol. 2002; 81 Suppl 2:S39-42.
Score: 0.034
-
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. Exp Hematol. 2001 Aug; 29(8):952-61.
Score: 0.033
-
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum Gene Ther. 2001 Apr 10; 12(6):659-70.
Score: 0.033
-
Cure of leukemia. Semin Hematol. 1999 Oct; 36(4 Suppl 7):73-83.
Score: 0.029
-
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
Score: 0.029
-
Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Mol Ther. 2016 04; 24(4):736-45.
Score: 0.023
-
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
Score: 0.021
-
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes. Mol Ther. 2014 Jun; 22(6):1134-1138.
Score: 0.020
-
Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May; 67(5):933-8.
Score: 0.019
-
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
Score: 0.016
-
Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy. Blood. 1989 Nov 15; 74(7):2335-42.
Score: 0.015
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.012
-
Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998 Apr; 12(2):339-57.
Score: 0.007
-
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol. 1998; 9 Suppl 5:S129-32.
Score: 0.006
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.005